Production & Sales

01 Dec 2020
- Production & Sales
- Manufacturing
SAB Biotherapeutics awarded $57.5m from BARDA and US Department of Defense for SAB-185

By PBR Staff Writer

SAB Biotherapeutics (SAB) as part of Operation Warp Speed, the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, and the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) have awarded SAB $57.5 million in expanded scope for its DiversitAb Rapid Response Antibody Program contract for the manufacturing of SAB-185, the company’s clinical stage therapeutic candidate for COVID-19.
30 Nov 2020
Production & Sales
Marketing & Sales
Dr. Reddy’s to acquire select anti-allergy brands from Glenmark in Russia, Ukraine, Kazakhstan and Uzbekistan

By PBR Staff Writer

Dr. Reddy’s Laboratories has entered into a definitive agreement with Glenmark Pharmaceuticals to acquire, subject to completion of certain precedent actions and closing activities, brands Momat Rino (for Russia, Kazakhstan and Uzbekistan), Momat Rino Advance (for Russia), Momat A (for Kazakhstan and Uzbekistan), Glenspray and Glenspray Active (for Ukraine), along-with rights to the trademarks, dossiers and patents for the territories mentioned.
26 Nov 2020
Production & Sales
Marketing & Sales
EC approves agreement for purchase of Covid-19 vaccine candidate from Moderna

By PBR Staff Writer

The European Commission (EC) has approved an agreement to purchase an initial 80 million doses of mRNA-1273, a vaccine candidate against Covid-19, from Moderna.
18 Nov 2020
Production & Sales
Marketing & Sales
Moderna announces supply agreement with UK government to supply Covid-19 mRNA vaccine

By PBR Staff Writer

Moderna, a new generation of transformative medicines for patients, today announced a supply agreement with the UK government to supply mRNA-1273, its Covid-19 vaccine candidate, beginning in March 2021 if it is approved for use by UK regulatory authorities.
02 Nov 2020
Production & Sales
Manufacturing
Mylan and Pfizer receive FTC clearance for Mylan, Upjohn merger

By PBR Staff Writer

Mylan and Pfizer announced that the U.S. Federal Trade Commission (the “FTC”) accepted a proposed consent order, which concludes the FTC’s review of the proposed combination of Mylan and Pfizer’s Upjohn Business.
02 Nov 2020
Production & Sales
Marketing & Sales
Cheplapharm to buy AstraZeneca’s heart failure and hypertension drugs for $400m

By PBR Staff Writer

Cheplapharm Arzneimittel has agreed to acquire commercial rights of heart failure and hypertension drugs from AstraZeneca in a deal valued at around $400m.
29 Oct 2020
Production & Sales
Marketing & Sales
Eli Lilly secures $375m contract from US government to supply Covid-19 drug

By PBR Staff Writer

Eli Lilly has secured a $375m contract from the US government to supply 300,000 doses of its bamlanivimab (LY-CoV555) 700mg investigational neutralising antibody to fight against Covid-19.
28 Oct 2020
Production & Sales
Marketing & Sales
GSK, Sanofi to supply 200 million doses of Covid-19 vaccine to COVAX

By PBR Staff Writer

GlaxoSmithKline (GSK) and Sanofi have entered into a statement of intent with Gavi to supply 200 million doses of their adjuvanted recombinant protein-based Covid-19 vaccine to the COVAX Facility.
27 Oct 2020
Production & Sales
Marketing & Sales
Moderna to supply Qatar with mRNA vaccine against Covid-19

By PBR Staff Writer

Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced a supply agreement with the Ministry of Public Health of Qatar for mRNA-1273, Moderna’s vaccine candidate against COVID-19, to support the Ministry’s ongoing efforts to secure early access to a safe and effective COVID-19 vaccine for the people of Qatar.
21 Oct 2020
Production & Sales
Manufacturing
JSR Life Sciences to expand KBI Biopharma and Selexis’ biologics manufacturing capabilities

By PBR Staff Writer

JSR Life Sciences is set to expand European gene-to-GMP biologics manufacturing facilities of its affiliate companies KBI Biopharma and Selexis in Geneva, Switzerland.

Drug Discovery

Research & Development

FDA approves Eli Lilly’s Jaypirca in relapsed or refractory CLL/SLL

AGC Biologics to expand cell line development with ATUM partnership

Clinical Trials

Patient Enrollment

US FDA approves Avacta Group’s IND application for AVA6000

AM-Pharma enrols first patients in Covid-19 phase III trial

Regulation

Drug Filing

Viatris files applications in Japan for approval of Effexor to treat GAD

Scholar Rock submits application of SMA therapy to FDA

Production & Sales

Manufacturing

ENCell and Lucy Biotech forge alliance for mesenchymal stem cell therapy

Merck introduces single-use reactor to accelerate ADC manufacturing

Packaging & Supply Chain

Packaging

Gerresheimer at CPHI Frankfurt 2025

Gerresheimer

Suppliers

No data found

Production & Sales

SAB Biotherapeutics awarded $57.5m from BARDA and US Department of Defense for SAB-185

Dr. Reddy’s to acquire select anti-allergy brands from Glenmark in Russia, Ukraine, Kazakhstan and Uzbekistan

EC approves agreement for purchase of Covid-19 vaccine candidate from Moderna

Moderna announces supply agreement with UK government to supply Covid-19 mRNA vaccine

Mylan and Pfizer receive FTC clearance for Mylan, Upjohn merger

Cheplapharm to buy AstraZeneca’s heart failure and hypertension drugs for $400m

Eli Lilly secures $375m contract from US government to supply Covid-19 drug

GSK, Sanofi to supply 200 million doses of Covid-19 vaccine to COVAX

Moderna to supply Qatar with mRNA vaccine against Covid-19

JSR Life Sciences to expand KBI Biopharma and Selexis’ biologics manufacturing capabilities

Pharmaceutical Business review is using cookies

Research & Development

Patient Enrollment

Drug Filing

Manufacturing

Packaging

No data found